Potiga Whizzes Through Advisory Panel Review With Thorough Risk Management Plan
This article was originally published in The Pink Sheet Daily
Executive Summary
Despite urinary retention and a number of other concerning side effects, GlaxoSmithKline and Valeant's epilepsy drug ezogabine carries the day, based in part on a pledge to do a post-market observational safety study.